The Journal of Practical Medicine >

2025 , Vol. 41 >Issue 21: 3398 - 3404

DOI: https://doi.org/10.3969/j.issn.1006-5725.2025.21.015

Clinical Research

Effects of different frequencies of hemodiafiltration combined with high⁃flux hemodialysis on renal function， micro⁃inflammatory state and left ventricular function in patients with diabetic nephropathy after maintenance hemodialysis

  • Jing GAO ,
  • Jin ZHAO ,
  • Fan WANG ,
  • Kang. LIU
Expand
  • *.Hemodialysis Room，Zibo First Hospital，Zibo 255200，Shandong，China

Received date: 2025-08-13

  Online published: 2025-11-13

Fold

Abstract

Objective To investigate the effects of different hemodiafiltration （HDF） frequencies combined with high-flux hemodialysis （HFHD） on renal function， micro-inflammatory status， and left ventricular function in patients with diabetic nephropathy who have undergone maintenance hemodialysis （MHD）. Methods A total of 120 patients with diabetic nephropathy undergoing MHD between January 2022 and December 2024 were enrolled in the study and randomly divided into a study group and a control group using a random number table method， with 60 patients in each group. Both groups received HFHD. The control group received hemodiafiltration （HDF） once a month， whereas the study group received HDF once a week. The study evaluated the two groups in terms of therapeutic efficacy， renal function indices， calcium-phosphorus metabolism indices， micro-inflammatory status， left ventricular function indices， and the incidence of adverse reactions. Results The total response rate in the study group was significantly higher than that in the control group （P < 0.05）. Following treatment， the levels of serum creatinine （Scr）， cystatin C （Cys C）， and 24-hour urine protein quantification （24hUP） in the study group were significantly lower than those in the control group （P < 0.05）. After treatment， the blood calcium level in the study group was higher， whereas the blood phosphorus level was lower compared to the control group （P < 0.05）. Additionally， post-treatment levels of interleukin-8 （IL-8）， IL-6， and tumor necrosis factor-α （TNF-α） in the study group were significantly reduced in comparison to the control group （P < 0.05）. The study group also exhibited improved cardiac function after treatment， as evidenced by a higher left ventricular ejection fraction （LVEF）， and reduced left ventricular end-diastolic diameter （LVDD） and left ventricular end-systolic diameter （LVSD） compared to the control group （P < 0.05）. There was no statistically significant difference in the incidence of adverse reactions between the two groups ［8.33% （5/60） vs. 11.67% （7/60）， P > 0.05］. Conclusion Combining once-weekly HDF with HFHD can enhance therapeutic outcomes and renal function， promote the recovery of calcium-phosphorus metabolism， alleviate the micro-inflammatory state， and improve left ventricular function in MHD patients with diabetic nephropathy.

Key words： maintenance hemodialysis; high-flux hemodialysis; diabetic nephropathy; hemodiafiltration; renal function; micro-inflammatory state; left ventricular function

Cite this article

Jing GAO , Jin ZHAO , Fan WANG , Kang. LIU . Effects of different frequencies of hemodiafiltration combined with high⁃flux hemodialysis on renal function， micro⁃inflammatory state and left ventricular function in patients with diabetic nephropathy after maintenance hemodialysis[J]. The Journal of Practical Medicine, 2025 , 41(21) : 3398 -3404 . DOI: 10.3969/j.issn.1006-5725.2025.21.015

References

[1] DWIVEDI S， SIKARWAR M S. Diabetic Nephropathy： Pathogenesis， Mechanisms， and Therapeutic Strategies［J］. Horm Metab Res， 2025， 57（1）：7-17. doi:10.1055/a-2435-8264
[2] GONG X， LIU J， GUO H， et al. Clinical efficacy of losartan potassium combined with alprostadil in early diabetic nephropathy and its effect on renal function［J］. Pak J Med Sci， 2025， 41（6）：1567-1571. doi:10.12669/pjms.41.6.10796
[3] 徐智君， 周清平， 梁振宁， 等. 基于COM-B模型的维持性血液透析患者自我管理行为影响路径研究［J］. 实用医学杂志， 2023， 39（23）：3120-3126.
[4] WANG J， LUO Y， JI X， et al. Effects of different hemodialysis modalities combined with low-calcium dialysate on mineral metabolism and vascular calcification in maintenance hemodialysis patients with chronic kidney disease［J］. J Appl Biomed， 2024， 22（4）：228-233. doi:10.32725/jab.2024.027
[5] PANG L， SUN S， SHI Y， et al. Research on the combined impact of high-flux dialysis and levocarnitine on the functionality of arteriovenous fistulas in patients undergoing maintenance hemodialysis［J］. Pak J Pharm Sci， 2025， 38（3）：781-788.
[6] BELMOUAZ M， GOUSSARD G， JOLY F， et al. Comparison of High-Flux， Super High-Flux， Medium Cut-Off Hemodialysis and Online Hemodiafiltration on the Removal of Uremic Toxins［J］. Blood Purif， 2023， 52（3）：309-318. doi:10.1159/000526891
[7] AHLMANN C， STRONACH L， WATERS K， et al. Hemodiafiltration for children with stage 5 chronic kidney disease： Technical aspects and outcomes［J］. Pediatr Nephrol， 2024， 39（9）：2611-2626. doi:10.1007/s00467-024-06285-w
[8] MA S， PU N， MA J. Effects of high-flux hemodialysis and hemodiafiltration on the mortality of patients with end-stage kidney disease： A meta-analysis［J］. Ren Fail， 2023， 45（1）： 2147436. doi:10.1080/0886022x.2022.2147436
[9] MITCHELL C R， HORNIG C， CANAUD B. Systematic review to compare the outcomes associated with the modalities of expanded hemodialysis （HDx） versus high-flux hemodialysis and/or hemodiafiltration （HDF） in patients with end-stage kidney disease （ESKD）［J］. Semin Dial， 2023， 36（2）： 86-106. doi:10.1111/sdi.13130
[10] SHLIPAK M G， TUMMALAPALLI S L， BOULWARE L E， et al. The case for early identification and intervention of chronic kidney disease： Conclusions from a kidney disease： Improving global outcomes （KDIGO） controversies conference［J］. Kidney Int， 2021， 99（1）： 34-47.
[11] SONG L， CHEN J， XU J， et al. Haemodynamically irrelevant pericardial effusion is associated with increased mortality in maintenance hemodialysis patients with end-stage renal disease［J］. BMC Nephrol， 2025， 26（1）：308. doi:10.1186/s12882-025-04233-w
[12] ANDARDEWI M F， LEGIAWATI L， WAHYUDI D T， et al. The Severity， Quality of Life， and Correlated Factors of Chronic Kidney Disease-associated Pruritus between Hemodialysis and Kidney Transplant Patients： A Cross-sectional Study［J］. Acta Med Indones， 2024， 56（2）：176-184.
[13] LIU Y， WEI Z， JING L， et al. Associations between dyadic coping， mutuality， and quality of life among maintenance hemodialysis patients and caregivers： An actor-partner interdependence mediation model［J］. Qual Life Res， 2025， 34（8）：2393-2404. doi:10.1007/s11136-025-03991-2
[14] 母元梅， 赵佳圆， 张莹. C反应蛋白/白蛋白比值与维持性血液透析患者心血管事件风险的关系［J］. 实用医学杂志， 2024， 40（1）：72-78.
[15] CANAUD B， STRIPPOLI G， DAVENPORT A. High-Volume Hemodiafiltration Versus High-Flux Hemodialysis： A Narrative Review for the Clinician［J］. J Clin Med， 2025， 14（8）： 2614. doi:10.3390/jcm14082614
[16] FENG H， WANG J， XIANG Y， et al. Effect of Hemodialysis Combined With Hemodiafiltration on Cardiac Structure， Function， and Metabolic Indicators in Uremic Patients［J］. Br J Hosp Med （Lond）， 2025， 86（5）：1-15. doi:10.12968/hmed.2024.0928
[17] 刘倩， 蒲萌萌， 杨凯， 等. 不同频率血液透析滤过联合高通量血液透析治疗尿毒症的效果分析及对预后的影响［J］. 中国现代医学杂志， 2023， 33（6）：71-76.
[18] BAL A Z， BAL U， AKDOGAN M， et al. The effect of paricalcitol and calcitriol with or without calcimimetics on pulse wave velocity and serum levels for parathyroid hormone， calcium and phosphorus in maintenance hemodialysis patients［J］. Acta Endocrinol （Buchar）， 2023， 19（4）： 480-486. doi:10.4183/aeb.2023.480
[19] ZHENG F Y， TAN Y Y， ZHOU J J. Effect of Paricalcitol Combined with Cinacalcet on Calcium and Phosphorus Metabolism in Patients Receiving Maintenance Hemodialysis［J］. Clin Pharmacol Drug Dev， 2024， 13（1）：96-102. doi:10.1002/cpdd.1328
[20] JIANG X， SUN F， HUANG H. Clinical Efficacy and Long-term Prognosis of High Flux Hemodialysis Combined with Different Frequency Hemodiafiltration in the Treatment of Middle-Aged and Elderly Patients with Uremia［J］. Iran J Kidney Dis， 2024， 18（1）：36-44.
[21] RAYEGO-MATEOS S， RODRIGUES-DIEZ R R， FERNANDEZ-FERNANDEZ B， et al. Targeting inflammation to treat diabetic kidney disease： The road to 2030［J］. Kidney Int， 2023， 103（2）：282-296. doi:10.1016/j.kint.2022.10.030
[22] KREINER F F， KRAAIJENHOF J M， VON HERRATH M， et al. Interleukin 6 in diabetes， chronic kidney disease， and cardiovascular disease： Mechanisms and therapeutic perspectives［J］. Expert Rev Clin Immunol， 2022， 18（4）： 377-389. doi:10.1080/1744666x.2022.2045952
[23] 李道新， 熊飞， 李红波， 等. 维持性血液透析患者微炎症状态及外周血 Keap1-Nrf2-ARE表达对导管相关性血流感染的诊断价值［J］. 中华医院感染学杂志， 2023， 33（1）： 49-53.
[24] XIA Y， LIU X. The value of lung ultrasound score combined with echocardiography in assessing right heart function in patients undergoing maintenance hemodialysis and experiencing pulmonary hypertension［J］. BMC Cardiovasc Disord， 2025， 25（1）： 33. doi:10.1186/s12872-025-04482-5
[25] WEN Y， XIA Y， GONG Y. Effects and safety of Sacubitril/Valsartan （SV） on heart function and blood pressure in maintenance hemodialysis （MHD） patients［J］. Am J Transl Res， 2022， 14（5）： 3439-3447.
Options
Outlines

/

〈 〉